CME Group Inc.

NasdaqGS:CME Rapport sur les actions

Capitalisation boursière : US$104.5b

CME Group Croissance future

Future contrôle des critères 0/6

CME Group devrait augmenter ses bénéfices et son chiffre d'affaires de 3.3% et de 4.7% par an respectivement. Le BPA devrait croître de de 4.7% par an. Le rendement des capitaux propres devrait être 15.9% dans 3 ans.

Informations clés

3.3%

Taux de croissance des bénéfices

4.65%

Taux de croissance du BPA

Capital Markets croissance des bénéfices11.8%
Taux de croissance des recettes4.7%
Rendement futur des capitaux propres15.87%
Couverture par les analystes

Good

Dernière mise à jour07 May 2026

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Mise à jour de l'analyse • Apr 27

CME: Volatile Street Views And New Futures Will Shape Trading Mix

Analysts have nudged their fair value estimate for CME Group down to $308.20 from $311.67, reflecting slightly softer revenue growth assumptions and a higher discount rate, partly balanced by a higher projected profit margin and a modestly lower future P/E, in line with the mix of recent price target trims and increases across the Street. Analyst Commentary Recent Street research on CME Group has been active on both sides, with several firms adjusting price targets and ratings in different directions.
Seeking Alpha • Apr 23

CME Group Q1 Earnings Show Strength, But The Stock Still Looks Expensive

Summary CME Group delivered record Q1 volumes and revenue but missed consensus EPS and revenue estimates by narrow margins. CME remains a hold; the stock’s premium valuation already prices in strong volumes, steady cash flows, and its competitive moat. Growth is driven by diverse product expansion, including commodities, crypto, and cross-margining, but near-term upside is limited absent a volatility or trading surge. Key risks are volume normalization, regulatory changes, and tech disruptions; current price fairly reflects both strengths and risks. Read the full article on Seeking Alpha
Mise à jour de l'analyse • Apr 11

CME: Volatility And New Contracts Will Shape Rare Earths And Crypto Volumes

The updated analyst price target for CME Group has moved higher by about $5 to $311.67. This change reflects analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a marginally higher future P/E multiple, even as they factor in a small trim to projected profit margins.
Mise à jour de l'analyse • Mar 26

CME: Volatility And New Contracts Will Shape Rare Earths And Volume Mix

Analysts have made a modest upward adjustment to the CME Group fair value estimate to about $307 from roughly $305, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin, and future P/E following a mix of recent rating changes and price target tweaks across the Street. Analyst Commentary Recent research on CME Group reflects a mixed but generally balanced backdrop, with several firms adjusting ratings and price targets in different directions.
Mise à jour de l'analyse • Mar 11

CME: Volatility And New Contracts Will Shape Rare Earths And Clearing Outlook

Our analyst price target for CME Group has moved modestly higher to $305.21 from $299.29, as analysts factor in slightly stronger modeled revenue growth and profitability. This is partially offset by a more conservative future P/E assumption and mixed views on volume drivers across product lines.
Mise à jour de l'analyse • Feb 25

CME: Volatility And New Contracts Will Shape Futures And Clearing Outlook

The analyst price target for CME Group edges higher to $232, with recent updates reflecting analysts' focus on firmer commodities volumes, as well as a more expense conscious outlook in their refreshed earnings models. Analyst Commentary Recent Street research around CME Group reflects a mix of optimism on volumes and earnings power, alongside caution on valuation and the cost base.
Mise à jour de l'analyse • Feb 10

CME: Volatility And Prediction Markets Will Guide Futures And Clearing Expansion Outlook

The updated analyst price target for CME Group edges higher to about US$297 from roughly US$290, reflecting analysts' use of a slightly lower discount rate, a modestly higher assumed revenue growth rate, and a similar future P/E multiple despite a slightly lower profit margin input. Analyst Commentary Street research on CME Group in recent sessions centers on a cluster of revised price targets and at least one rating change, with several bullish analysts lifting their targets by varying dollar amounts and one major bank fine tuning its view in both directions over a short time frame.
Mise à jour de l'analyse • Jan 27

CME: Volatility And Prediction Markets Will Shape Futures Activity Outlook

The analyst price target for CME Group is now US$290.40, a move of about US$2 from the prior US$288.33, as analysts factor in slightly different assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E following mixed recent research that includes both a modest target cut and an upgrade linked to a tilt toward volatility. Analyst Commentary Recent research on CME Group reflects a mix of optimism and caution, with one firm trimming its price target slightly and another upgrading the stock on what it sees as a better setup for volatility related trading activity.
Mise à jour de l'analyse • Jan 12

CME: Fee Moat And Prediction Markets Will Shape Futures Activity Outlook

Narrative Update: CME Group CME Group's fair value estimate has edged up by about $1 to roughly $288 per share, as analysts cite the company's strong futures and options moat, a higher price target range of up to $314, and interest in its role within prediction markets as key supports for the updated outlook. Analyst Commentary Recent Street research has been generally constructive on CME Group, with several bullish analysts adjusting their price targets higher and highlighting the company's futures and options franchise as a key support for valuation.
Mise à jour de l'analyse • Dec 27

CME: Fee Resilience And Prediction Markets Will Balance Lower Volatility Risks

Analysts have nudged their average price target on CME Group modestly higher, to approximately $287 from about $286, citing the company’s resilient fee-based revenue mix, strong competitive moat in futures and options, and supportive demand signals from prediction market partnerships despite some conflicting views on near term volume volatility. Analyst Commentary Recent Street research presents a mixed but generally constructive view on CME Group, with upward moves in price targets tempered by concerns around volume sensitivity and valuation risk if volatility normalizes.
Mise à jour de l'analyse • Dec 13

CME: Fee Resilience And New Prediction Markets Will Help Navigate Volatility

Analysts have raised their fair value estimate for CME Group by about $1 to roughly $286 per share, citing the company’s resilient clearing and transaction fee driven revenue base, modestly higher long term growth expectations, and a reinforced competitive moat highlighted in recent target revisions across the Street. Analyst Commentary Street research on CME Group reflects a wide range of views on valuation and execution, with recent target changes clustering around expectations for resilient fee income but diverging on the sustainability of growth and the impact of lower volatility.
Mise à jour de l'analyse • Nov 16

CME: Revenue Resilience And New Ventures Will Balance Volatility Risks Ahead

The average analyst price target for CME Group was raised by approximately $3 to $285, as analysts point to the firm's resilient revenue streams and strong market position amid continued macroeconomic uncertainty. Analyst Commentary Recent analyst activity reflects a mix of optimism and caution regarding CME Group's performance and outlook, particularly as the firm navigates shifting macroeconomic and market conditions.
Seeking Alpha • Apr 27

CME: More Market Volatility Equals More Demands - Initiating With Strong Buy

Summary Initiating a 'Strong Buy' rating for CME with a fair value of $301 per share due to increased demand for hedging amid economic uncertainty and market volatility. CME's diverse product offerings and strong trading volume growth, particularly in interest rate options/futures, equity, FX, energy, and commodities, support its robust business model. CME's high operating margin, capex-light business model, and strategic use of Google Cloud enhance profitability and operational efficiency. Key risks include potential pushback on market data price increases and competition from FMX Futures Exchange in the US treasury market. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

CME Group At A New All-Time High - Valuation Concerns Justified?

Summary CME shares have delivered market-beating returns over the past two years, prompting the question of whether it's time to lock in profits. In this update, I discuss whether the rally appears sustainable against the backdrop of the 2024 results published in mid-February. The analysis focuses on average contract volumes and rates, signs of potential underinvestment given the surprisingly strong free cash flow, and includes an update on debt and leverage. I explain why I do not intend to sell my CME stock position despite the elevated valuation, and why I am not even considering a covered call strategy at this time. Read the full article on Seeking Alpha
Seeking Alpha • Feb 18

CME Group: High Quality With Good Dividend Yield

Summary CME Group's near-monopoly in futures and options trading, with extraordinary 60% FCF margins, makes it a high-quality, capital-light business despite regulatory costs. Significant acquisitions like CBOT, NYMEX, and KCBT have solidified CME's market dominance, though future focus will be on dividends and smaller acquisitions. CME is slightly undervalued with a 4% dividend yield, making it a strong hold for dividend-focused investors seeking a high-quality business model. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:CME - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20287,7274,5135,2155,1867
12/31/20277,3304,4254,9094,93112
12/31/20267,0414,3894,6274,66512
3/31/20266,7444,2454,3294,420N/A
12/31/20256,5074,0214,1944,277N/A
9/30/20256,3853,7174,0844,161N/A
6/30/20256,4333,7214,1074,196N/A
3/31/20256,2743,5813,8263,914N/A
12/31/20246,1203,4823,5973,691N/A
9/30/20246,0343,4223,6283,717N/A
6/30/20245,7883,2623,4923,571N/A
3/31/20245,6163,1573,3633,444N/A
12/31/20235,5793,1863,3773,454N/A
9/30/20235,3383,0113,3113,391N/A
6/30/20235,2282,9423,1083,192N/A
3/31/20235,1042,8283,0783,159N/A
12/31/20225,0192,6572,9663,056N/A
9/30/20224,8332,6332,6502,743N/A
6/30/20224,7152,8892,6162,717N/A
3/31/20224,6572,7452,4772,599N/A
12/31/20214,6902,6172,2752,402N/A
9/30/20214,6302,4352,2252,394N/A
6/30/20214,6001,9201,8882,074N/A
3/31/20214,6031,9132,3782,561N/A
12/31/20204,8842,1052,5182,716N/A
9/30/20204,9112,1512,5812,775N/A
6/30/20205,1092,3753,0713,274N/A
3/31/20205,2002,3862,5212,761N/A
12/31/20194,8682,117N/A2,673N/A
9/30/20194,9592,033N/A2,464N/A
6/30/20194,5881,808N/A2,236N/A
3/31/20194,3771,860N/A2,285N/A
12/31/20184,3091,962N/A2,441N/A
9/30/20183,9734,516N/A2,391N/A
6/30/20183,9594,413N/A2,316N/A
3/31/20183,8244,262N/A2,057N/A
12/31/20173,6454,063N/A1,751N/A
9/30/20173,6581,498N/A1,801N/A
6/30/20173,6091,662N/A1,773N/A
3/31/20173,5901,566N/A1,732N/A
12/31/20163,5951,534N/A1,732N/A
9/30/20163,4961,452N/A1,607N/A
6/30/20163,5051,340N/A1,591N/A
3/31/20163,4181,284N/A1,626N/A
12/31/20153,3271,247N/A1,533N/A
9/30/20153,3541,262N/A1,644N/A
6/30/20153,2661,192N/A1,414N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CME ( 3.3% par an) est inférieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de CME ( 3.3% par an) devraient croître plus lentement que le marché US ( 16.6% par an).

Croissance élevée des bénéfices: Les bénéfices de CME devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CME ( 4.7% par an) devrait croître plus lentement que le marché de US ( 11.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CME ( 4.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de CME devrait être faible dans 3 ans ( 15.9 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/07 18:28
Cours de l'action en fin de journée2026/05/07 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

CME Group Inc. est couverte par 34 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Stephen BiggarArgus Research Company
Benjamin BudishBarclays
Roger FreemanBarclays